Default company panoramic image

Embera NeuroTherapeutics, Inc.

Embera is a specialty pharma company developing a novel treatment for the $1.9B smoking cessation market and cocaine dependence (no approved treatments today).

  • Stage Product In Development
  • Industry Biotechnology
  • Location Sudbury, MA, USA
  • Currency USD
  • Founded January 2007
  • Employees 1
  • Website

Company Summary

Embera is developing a patented drug combination to address 2 significant unmet medical needs smoking and cocaine dependence. Embera is advancing EMB-001 for smoking cessation ($1.9B WW market), based on positive animal study results where EMB-001 compared very favorably to Chantix®, Pfizer’s $638M smoking cessation drug. Embera is also developing the cocaine dependence indication for EMB-001 a $400M product opportunity leveraging grant funding.


  • Bd6b1b53 098c 4fd6 9d29 431f5f6cdd34
    President & CEO

  • 69ad4d96 ccf7 40f4 8893 ca3bc9b6bafe
    VP Preclinical Development & Regulatory Affairs

  • 4f0c5db7 4fc2 4803 b52c dd64e5bd4d20
    Director of Clinical Operations

  • 616aa877 6ad5 4151 b5b9 4a4b23feb0cb
    Chief Medical Officer

  • Default avatar
    Michael Short
    VP of Strategy and Business Development


  • Default avatar
    Gunderson Dettmer Stough, Villeneuve Franklin & Hachigian, LLP
    Default avatar
    Hummingbird & King

Previous Investors

  • Default avatar
    Joe Lovett, Louisiana Fund I
    Managing Director
    11e290cc 1ac6 432e a602 351a816a0a5b
    Managing Director, Louisiana Ventures, Themelios Ventures